Nautilus Biotechnology (NAUT) vs Palisade Bio (PALI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Nautilus Biotechnology (NAUT) has outperformed Palisade Bio (PALI) over the past year, gaining 101.8% versus a loss of 27.5%. Over five years, NAUT leads with a -68.1% price change compared with -99.9% for PALI. Palisade Bio is the larger company by market cap ($252.7 million vs $231.6 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NAUT | PALI |
|---|---|---|
| Share price | $1.82 | $1.45 |
| Market cap | $231.60M | $252.69M |
| 1-day change | -7.14% | -2.03% |
| YTD return | -6.67% | -38.30% |
| 1-year return | +101.77% | -27.50% |
| 5-year return | -68.13% | -99.93% |
| P/E ratio (TTM) | — | 2.42 |
| EPS (TTM) | $-0.45 | $0.60 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $4.31 | $2.86 |
| 52-week low | $0.82 | $1.32 |
| Distance from 52-week high | -57.77% | -49.30% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +110.44% | +604.83% |
| Average volume | 2.66M | 2.56M |
| Shares outstanding | 127.26M | 174.27M |
| Employees | 127 | 14 |
| Sector | Industrials | Health Care |
| Industry | Biotechnology: Laboratory Analytical Instruments | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NAUT has outperformed PALI by 129.3 percentage points over the past year.
- The two companies sit in different sectors: Nautilus Biotechnology in Industrials and Palisade Bio in Health Care.
About Nautilus Biotechnology
NAUT stock →Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome in the United States. The company develops Nautilus Voyager Platform, which includes an end-to-end solution comprising instruments, reagents, consumables, and software analysis.
Industrials · Biotechnology: Laboratory Analytical Instruments · 127 employees
About Palisade Bio
PALI stock →Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States. Its lead clinical product candidate includes PALI-2108, which is in phase 1b clinical trial to treat patients with inflammatory bowel disease, including ulcerative colitis and Fibrostenotic Crohn's disease.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 14 employees
NAUT vs PALI FAQ
Which is bigger, Nautilus Biotechnology or Palisade Bio?
Palisade Bio (PALI) is larger, with a market capitalization of $252.69M compared with $231.60M for Nautilus Biotechnology (NAUT).
Which stock has performed better over the past year, NAUT or PALI?
NAUT returned +101.77% over the past 12 months, compared with -27.50% for PALI (price return, excluding dividends). Past performance does not predict future results.
Are Nautilus Biotechnology and Palisade Bio in the same industry?
No. Nautilus Biotechnology is in the Industrials sector, while Palisade Bio is in Health Care.